Genzyme Corp.
500 Kendall Street
Cambridge,
MA 02142
Phone: 617-252-7500
Fax: 617-252-7600
Web Site: http://www.genzyme.com
| REUTERS ABRIDGED BUSINESS SUMMARY | |
| Genzyme Corporation operates as a biotechnology company worldwide. The companys Genetic Diseases segment manufactures and distributes therapeutic products, including Cerezyme as an enzyme replacement therapy for the treatment of Type 1 and Type 3 Gaucher diseases; Fabrazyme, a recombinant form of the human enzyme alpha-galactosidase for the treatment of Fabry disease; Myozyme as a therapy for Pompe disease; and Aldurazyme for the treatment of Mucopolysaccharidosis I. This segment sells its products directly to physicians, hospitals, treatment centers, and government agencies through distributors. Its Cardiometabolic and Renal segment offers products consisting of Renagel and Renvela for the control of serum phosphorus in patients with chronic kidney disease on dialysis; Hectorol, a line of vitamin D2 pro-hormone products for the treatment of secondary hyperparathyroidism; and Thyrogen, an adjunctive diagnostic agent used in the follow-up of patients with well-differentiated thyroid cancer. This segment sells its products to retail pharmacies, hospitals, and other providers of medication to patients. The companys Biosurgery segment provides biotherapeutics and biomaterial-based products, which comprise Synvisc, a biomaterial-based product that is used to treat the pain associated with osteoarthritis of the knee; and Sepra family of products to prevent adhesions following various surgical procedures in the abdomen and pelvis. Its Hematologic Oncology segment develops products for the treatment of cancer, which include Campath for the treatment of B-cell chronic lymphocytic leukemia; Clolar for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia; and Mozobil for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. It has a collaboration agreement with to-BBB technologies BV. The company was founded in 1981 and is based in Cambridge, Massachusetts. |
|
| Key Statistics | |
| |
| | Pay | Exercised | Mr. Henri A. Termeer , 63
Exec. Chairman, Chief Exec. Officer and Pres |
$
3.54M |
$
0 | Mr. Michael S. Wyzga , 54
Chief Financial Officer and Exec. VP of Fin. |
$
999.00K |
$
1.36M | Mr. Sandford D. Smith , 62
Pres of International Group |
$
979.00K |
$
711.00K | Mr. Peter Wirth Esq., 59
Exec. VP of Corp. Devel. & Legal and Sec. |
$
1.22M |
$
0 | Mr. Earl M. Collier Jr., 62
Part-Time Sr. Advisor |
$
1.05M |
$
3.54M |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.38 (0.70%) 
Profile
Help
